deaths (OS)progression or deaths (PFS)RFS/DFS

la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)

versus lapatinib plus capecitabine
trastuzumab emtansine vs. lapatinib plus capecitabine 1 certainty unassessablestatistically conclusive-29% certainty unassessablestatistically conclusive-32%-